Global Inactivated Vaccines Market Size Study, By Vaccine Type, By Method of Inactivation, By Route of Administration, By End-User, and Regional Forecasts 2022-2032

Description

Global Inactivated Vaccines Market was valued at approximately USD 40.67 billion in 2023 and is projected to witness a steady compound annual growth rate (CAGR) of 5.72% during the forecast period from 2024 to 2032. Inactivated vaccines, crafted from pathogens that have been neutralized so they no longer pose a threat of infection, play a pivotal role in modern immunization practices. They provide a safer alternative for individuals with compromised immune systems, such as those with chronic conditions or undergoing treatments that weaken immune function. The primary mechanism of these vaccines is to stimulate an immune response by introducing a deactivated version of the pathogen, ensuring the body can recognize and combat the actual disease if exposed in the future.

The Global Inactivated Vaccines Market growth is significantly driven by the rising incidence of infectious diseases globally and the escalating number of clinical research initiatives focused on developing more efficient and accessible vaccines. Inactivated vaccines require multiple doses to maintain immunity over time, making them integral to long-term disease prevention strategies. Inactivated vaccines offer a robust solution that minimizes potential side effects while delivering effective immunization. In addition, advancements in vaccine development are anticipated to create lucrative opportunities for the market. However, stringent regulatory requirements is going to impede the overall demand for the market during the forecast period 2024-2032.

The key regions considered for the market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America have led the charge in the adoption and development of inactivated vaccines due to a strong healthcare framework and significant investment in healthcare innovation. The ongoing efforts by the U.S. and Canadian governments to bolster their healthcare sectors, especially in the domain of vaccine development, are projected to maintain the dominance of these regions. Meanwhile, emerging markets in Asia-Pacific are also witnessing substantial growth, driven by increased awareness of vaccination and significant advancements in healthcare infrastructure, which are expected to contribute to the market's expansion.

Major market players included in this report are:

Mylan N.V.
Boehringer Ingelheim International GmbH
Merck & Co., Inc.
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Bharat Biotech
Serum Institute of India
GSK plc
Novartis AG
Sanofi S.A.

The detailed segments and sub-segment of the market are explained below:

By Vaccine Type:

Viral Vaccine
Bacterial Vaccine

By Method of Inactivation:

Solvent Detergent Method
Radiation Method
pH Concentration
Others

By Route of Administration:

Oral
Subcutaneous
Intravenous

By End-User:

Hospitals
Specialty Clinics
Homecare Settings
Others

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

Chapter 1. Global Inactivated Vaccines Market Executive Summary

1.1. Global Inactivated Vaccines Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Vaccine Type
- 1.3.2. By Method of Inactivation
- 1.3.3. By Route of Administration
- 1.3.4. By End-User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Inactivated Vaccines Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Inactivated Vaccines Market Dynamics

3.1. Market Drivers
- 3.1.1. Rise in Incidence of Infectious Diseases
- 3.1.2. Increasing Number of Clinical Research Activities
3.2. Market Challenges
- 3.2.1. Stringent Regulatory Requirements
3.3. Market Opportunities
- 3.3.1. Technological Advancements in Vaccine Development
- 3.3.2. Expansion in Emerging Markets

Chapter 4. Global Inactivated Vaccines Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Inactivated Vaccines Market Size & Forecasts by Vaccine Type 2022-2032

5.1. Segment Dashboard
5.2. Global Inactivated Vaccines Market: Vaccine Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Viral Vaccine
- 5.2.2. Bacterial Vaccine

Chapter 6. Global Inactivated Vaccines Market Size & Forecasts by Method of Inactivation 2022-2032

6.1. Segment Dashboard
6.2. Global Inactivated Vaccines Market: Method of Inactivation Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Solvent Detergent Method
- 6.2.2. Radiation Method
- 6.2.3. pH Concentration
- 6.2.4. Others

Chapter 7. Global Inactivated Vaccines Market Size & Forecasts by Route of Administration 2022-2032

7.1. Segment Dashboard
7.2. Global Inactivated Vaccines Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Oral
- 7.2.2. Subcutaneous
- 7.2.3. Intravenous

Chapter 8. Global Inactivated Vaccines Market Size & Forecasts by End-User 2022-2032

8.1. Segment Dashboard
8.2. Global Inactivated Vaccines Market: End-User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Hospitals
- 8.2.2. Specialty Clinics
- 8.2.3. Homecare Settings
- 8.2.4. Others

Chapter 9. Global Inactivated Vaccines Market Size & Forecasts by Region 2022-2032

9.1. North America Inactivated Vaccines Market
- 9.1.1. U.S. Inactivated Vaccines Market
- 9.1.2. Canada Inactivated Vaccines Market
9.2. Europe Inactivated Vaccines Market
- 9.2.1. UK Inactivated Vaccines Market
- 9.2.2. Germany Inactivated Vaccines Market
- 9.2.3. France Inactivated Vaccines Market
- 9.2.4. Spain Inactivated Vaccines Market
- 9.2.5. Italy Inactivated Vaccines Market
- 9.2.6. Rest of Europe Inactivated Vaccines Market
9.3. Asia-Pacific Inactivated Vaccines Market
- 9.3.1. China Inactivated Vaccines Market
- 9.3.2. India Inactivated Vaccines Market
- 9.3.3. Japan Inactivated Vaccines Market
- 9.3.4. Australia Inactivated Vaccines Market
- 9.3.5. South Korea Inactivated Vaccines Market
- 9.3.6. Rest of Asia Pacific Inactivated Vaccines Market
9.4. Latin America Inactivated Vaccines Market
- 9.4.1. Brazil Inactivated Vaccines Market
- 9.4.2. Mexico Inactivated Vaccines Market
- 9.4.3. Rest of Latin America Inactivated Vaccines Market
9.5. Middle East & Africa Inactivated Vaccines Market
- 9.5.1. Saudi Arabia Inactivated Vaccines Market
- 9.5.2. South Africa Inactivated Vaccines Market
- 9.5.3. Rest of Middle East & Africa Inactivated Vaccines Market

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. Mylan N.V.
  - 10.3.1.1. Key Information
  - 10.3.1.2. Overview
  - 10.3.1.3. Financial (Subject to Data Availability)
  - 10.3.1.4. Product Summary
  - 10.3.1.5. Market Strategies
- 10.3.2. Boehringer Ingelheim International GmbH
- 10.3.3. Merck & Co., Inc.
- 10.3.4. F. Hoffmann-La Roche AG
- 10.3.5. Bristol-Myers Squibb Company
- 10.3.6. Bharat Biotech
- 10.3.7. Serum Institute of India
- 10.3.8. GSK plc
- 10.3.9. Novartis AG
- 10.3.10. Sanofi S.A.

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes